| This paper analyzes the economic benefits per year and total economic benefits ofviral hepatitis vaccine immunization strategy in Haidian District of Beijing by usingcost-benefit analysis. To consolidate and improve the immunization plan and adopt thefeasible preventive measures for viral hepatitis, we carry out the comprehensiveeconomic evaluation of viral hepatitis vaccine immunization strategy in HaidianDistrict of Beijing by using the microeconomics' conceptions and methods.MethodsField survey: The basic data mainly comes from field surveys including surveyson total outpatient and inpatient costs of liver diseases including acute hepatitis a, acutehepatitis b, chronic hepatitis b, cirrhosis, primary hepatocellular carcinoma in Beijingin 2004 and the staff, infrastructure, finance, workload, capacity and qualityinformation of the hospitals with responsibility for vaccination in Haidian District ofBeijing.Deep interview: In my study, we ever interviewed the experts and specialists inliver diseases so as to know further and validate the prevalence feature and relatedprobability.Sample survey: The data about partial inpatient costs comes from the samplesurvey from sample hospitals on the 94 copies of inpatient medical records in 2004．Literature review: It mainly adopts literature review when setting transformationprobability among the different liver diseases. Based on five aspects of sex, age, area, career and time, we describe theprevalence features of viral hepatitis in Haidian District of Beijing. Simultaneously, wecarry out comprehensive analysis for the economic benefits of viral hepatitisvaccination. The research results show that under the present immunization strategy,Haidian District is estimated to prevent 729 persons from suffering HA between 1998and 2004 with hepatitis a vaccination. The benefit-cost ratio of population is 1:0．26,whereas the government is also benefiting from the input, so the total benefit-costratio is 1:1．64．Under the present immunization strategy, Haidian District is estimated to prevent4365 persons from suffering acute HB, 38148 persons from positive HBsAg, 9537persons from chronic HB, 954 persons from liver cirrhosis, 95 persons from livercancer between 1994 and 2004 with hepatitis a vaccination. The net benefit is 100．91million RMB, and the benefit-cost ratio 1:4．59．ConclusionsIt is important for the public to improve the level of hepatitis a antibody, controland decrease the incidence probability and prevalence hepatitis a. Although totalbenefit-cost ratio is 0．26:1 in the past seven years, the government is benefiting fromthe input and the benefit-cost ratio is 1．64:1．HA vaccine immunization generateseconomic benefit. It brings pretty good social benefit as well. The current strategy, i.e.government proposes, with the fees for vaccine and inoculation out of pocket, isfeasible. While it may improves the cost-benefit ratio by expanding inoculation tosome high-risk groups.Compared with the economic benefits of hepatitis a vaccination, hepatitis bvaccination generates considerable social benefits and economic benefits influenced bythe length of course of disease, easy to transform to chronic hepatitis b, cirrhosis, andprimary hepatocellular carcinoma and disease burden and so on. In the past elevenyears, total benefit-cost ratio is 4．59:1．By the sensitivity analysis, we can find out that if we append the vaccination scale, the benefit-cost ratio can be improved obviouslyand we need not add new human resources and material resources.Otherwise, the economic burden of liver diseases is great threat for the nationalbasic medicare fund and individuals. So it is necessary to reduce the burden for thenational medicare fund and individuals by viral hepatitis vaccination.
|
PDF Full Text Request